{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-26-000083","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2026-08-04T12:46:07+00:00","discovered_at":"2026-08-04T12:50:00.552556+00:00","generated_at":"2026-08-04T12:50:12.258549+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evolus expands Estyme HA gel rights to Canada, Australia, New Zealand; expects 2028 launch","bullets":["Upfront payment of €920,000 plus up to €1.38 million upon regulatory approvals.","Estyme complements Jeuveau/Nuceiva; combined neurotoxin & filler TAM ~$500M annually.","Commercialization expected in 2028, subject to applicable regulatory approvals.","Symatese responsible for development, manufacturing, and regulatory; Evolus pays mid-single digit royalty.","Agreement expected to be accretive to Evolus' international gross margins."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-26-000083","json":"https://secwatch.observer/filing/0001570562-26-000083.json","markdown":"https://secwatch.observer/filing/0001570562-26-000083.md","text":"https://secwatch.observer/filing/0001570562-26-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/0001570562-26-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/eols-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T12:50:12.258549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}